GlassScriptPhysician profile
Aakash Shah
NPI 1386059020
$40,556.69
in general payments reported to CMS, 2019-2025
20 companies · $2,700 in 2025
The $2,700 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $1,038 · 2021: $7,328 · 2022: $19K · 2023: $5,792 · 2024: $2,890 · 2025: $2,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,347 · Travel and Lodging: $3,535 · Grant: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,347.22 |
| Travel and Lodging | $3,534.66 |
| Grant | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18,435.34 | 2019-2025 | Aveir, Ensite Precision, Gallant |
| Boston Scientific Corporation | $15,384.71 | 2019-2025 | Versacross Access Solution, Rhythmia Mapping System |
| Medtronic, INC. | $3,440.27 | 2021-2025 | Arctic Front Advance, Corevalve Evolut R, Cobalt Dr Mri Surescan |
| Biosense Webster, INC. | $739.27 | 2023-2025 | Carto 3, Nuvision Ice Catheter |
| Abiomed | $731.61 | 2019-2020 | |
| Biotronik INC. | $305.60 | 2021-2022 | |
| Pfizer INC. | $219.88 | 2019-2020 | |
| Atricure, INC. | $219.58 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Heartflow, INC. | $204.73 | 2025 | |
| Cvrx, INC. | $197.62 | 2024 | Barostim Neo System |
| Amgen INC. | $129.76 | 2019-2020 | |
| Linvatec Corporation | $121.88 | 2019 | |
| Merck Sharp & Dohme LLC | $100.00 | 2019 | |
| Medtronic Vascular, INC. | $94.94 | 2019 | |
| Novo Nordisk INC | $71.58 | 2024 | Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $64.29 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.30 | 2025 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.85 | 2020-2025 | Lifevest |
| Tactile Systems Technology INC | $22.80 | 2024 | Entre Plus, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $21.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aakash Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.